Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Donanemab→

Donanemab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1931944-80-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Amyloid beta-directed humanised IgG1 monoclonal antibodyanti-amyloid biologic
Mechanism of action
Binds insoluble N-terminally truncated pyroglutamate amyloid beta in amyloid plaques and promotes their clearance through immune-mediated mechanisms. The therapeutic target is amyloid pathology; treatment does not reverse established neuronal loss.
Indications / reported uses
  • Treatment of Alzheimer disease in adults with mild cognitive impairment or mild dementia stage, with confirmed amyloid pathology, under the US product indication; MRI monitoring and risk-management requirements apply

Sources: US DailyMed — KISUNLA (donanemab-azbt) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Donanemab Environmental Risk Assessment (ERA) (the Donanemab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.